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Results: AV block was asymptomatic in 119 (84.4%) and complete in 100
(70.9%) patients. Incomplete AV block progressed to complete in 29 (70.7%)
patients with incomplete block over 2.8±3.4 years (1-155 months). Narrow
QRS complex was present in 18 of 26 patients (69.2%) with congenital, and
106 of 115 (92.2%) with childhood AV block. Pacemakers were implanted in
112 children (79.4%), during the first year of life in 18 (16.1%) and before 10
years of age in 90 (80.4%). The mean delay between diagnosis of AVB and
pacemaker implants was 2.6±3.9 years (0-300 months). The pacing indication
was prophylactic in 70 children (62.5%). During a median follow-up of
11.6±6.7 years (1-32 years), no patient died or developed dilated cardiomyop-
athy. The long-term follow-up was uncomplicated in 127 children (90.1%).
Conclusions: In this large multicenter study, the long-term outcome of con-
genital or childhood, isolated, non-immune AV block was favorable, regardless of
the patient’s age at the time of diagnosis. No patient died or developed dilated car-
diomyopathy, and pacemaker-related complications were few. The progression of
incomplete to complete AV block in nearly 70% of patients suggests a postnatal
degeneration of the specialized conduction system.
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Right ventricular (RV) failure is a major long-term complication of con-
genital heart disease, leading to morbidity and mortality. Since conventional
therapy gives poor results, cell therapy may be a therapeutic option for cardiac
repair. The ability of embryonic stem cells (ESC) differentiation towards a
cardiomyogenic phenotype makes them attractive candidates. Our aim was to
evaluate, in a large animal model, the effects of cardiac-committed human
ESC transplantation on the RV function.
A model of RV dysfunction was created in 8 piglets using a surgical pro-
cedure mimicking RV tract sequellae of repaired tetralogy of Fallot leading,
after 4 months, to a chronic combined RV overload. Four pigs received
vehicle and 4 others received HUES-24 derived human cardiac progenitors
cells injected at multiple sites into the free wall of RV myocardium. All pigs
were immunosuppressed using tacrolimus. Myocardial function was measured
3 months after cell transplantation by conductance catheter technique using
maximal elastance (Emax) slope and ventricular energetics (stroke work, pres-
sion-volume area). The risk of ventricular arrhythmia was evaluated by pro-
grammed ventricular stimulation at the end of the follow-up. Structural
remodelling was assessed by histological examination.
All pigs survived and no complication occurred related to either myocardial
injections or immunosuppression. No ventricular arrhythmia was induced. In all
treated pigs, myocardial contractility was improved as assessed by an increasing
Emax slope relative to controls at the follow-up end (0.58±0.03 vs 0.40±0.08, p<0.05)
whereas stroke work was similar in both groups. Improvement of contractility in
treated pigs occurred without increasing of pressure-volume area suggesting that the
myocardium is more efficient. In treated pigs, myocardial fibrosis appeared peritra-
becular whereas, in controls, it was found in peritrabecular and perimyocyte areas.
Cell therapy by multiple trans-epicardial injections of ESC derived human
cardiac progenitor cells in failed RV is feasible, improves RV myocardial con-
tractility and allows a better adaptation to chronic overload. 
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Introduction: Congenital long QT syndrome (LQTS) is a frequent cause
of sudden cardiac death in children without structural heart disease. Given the
recent progress in molecular diagnosis, a growing portion of LQTS patients is
genetically affected but still asymptomatic. Their clinical outcome has not
been clearly evaluated, and their optimal treatment is still discussed.
Methods: Our database was searched for all patients with genotyped
LQTS, identified by familial screening and aged 16 or less at diagnosis. We
retrospectively recorded demographic and electrocardiographic data, personal
and family histories and genetic diagnoses.
Results: 90 non proband children with genetically confirmed LQTS were
included. Mean age at diagnosis was 7,3±5,2 years, and mean follow-up dura-
tion was 4,6±4,3 years. 7 (7,8%) were symptomatic before diagnosis, and
4 (4,4%) experienced LQTS-related symptoms during follow-up. No sudden
cardiac death was reported. One LQT1 patient presented aborted cardiac arrest
while swimming. Beta-blocker therapy was initiated in 51 patients (56,7%).
Device therapy was infrequently used (one pacemaker, no implantable cardio-
verter defibrillator). Corrected QT interval (QTc) was the only factor corre-
lated to the risk of LQTS-related symptom (p=0,02). Initiation of betablocker
therapy was associated with mutations in KCNQ1 or KCNH2 (p<0,01), family
history of LQTS-related cardiac event in a first-degree relative (p=0,02), diag-
nosis before four months of age (p=0,01) and a longer QTc (p=0,0016).
Conclusion: Clinical outcome is favorable in genetically confirmed non
proband LQTS children, and similar to what has been previously described despite
less frequent use of beta blocker and device therapies. Thus, beta blocker therapy
should probably not be initiated systematically in such patients, especially when
QTc duration does not exceed 460 ms. ICD implantation does not seem manda-
tory in non proband LQT3 children, at least in their first years of life.
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Background: Managing vitamine K antagonist (VKA) therapy is chal-
lenging especially in children because of a narrow therapeutic range and a
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wide inter-individual variability in the dose requirement. Beside non-genetic
factors, polymorphisms in VKORC1, CYP2C9 and CYP4F2 genes have been
shown to affect warfarin dosing in adults. The aim of the study was to deter-
mine the relative contribution of non-genetic and genetic factors to warfarin
dose requirements in children and to evaluate the potential influence of these
factors on the anticoagulation quality control.
Methods: Consecutive children were prospectively enrolled if they
received long term warfarin therapy. By multivariate analyses, we assessed the
influence of genetic (CYP2C9, VKORC1 and CYP4F2) and non-genetic fac-
tors on the warfarin dose requirements and on the time spent within, above,
and below the INR range.
Results: 83 children receiving warfarin (median age 9.0 years) with a weekly
maintenance dose of 23.2±15.0 mg (3.5 mg-84 mg), i.e. 0.93±0.55 mg/kg, were
included. All patients had cardiac diseases. Height, INR ranges, VKORC1 and
CYP2C9 genotypes were retained in the final regression model, explaining
69.7% of the overall inter-individual variability in warfarin doses. In 86.7%.
of the patients, the difference between the observed dose and the dose pre-
dicted by the model was 1mg/day. The dose was overestimated in 8% of the
patients and underestimated in 5.3%. Of the whole cohort, 61 children had
INR values collected during the study period: the time spent within, above or
below the therapeutic INR range was 83.0±14.6%, 9.0±10.5%, and 7.1±8.9%,
respectively. No covariates were found associated with the anticoagulation
quality.
Conclusion: Height, INR range, VKORC1/CYP2C9 genotypes were the
main contributors of warfarin dose requirement, explaining more than 2/3 of
the variability. Genotyping in children requiring VKA treatment might be of
interest to optimize dosing of warfarin and follow-up.
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Background: Scimitar syndrome (Scim.) is a rare association of congenital
cardiopulmonary anomalies with anomalous drainage of one or more of the
right pulmonary veins to the inferior caval vein. Pulmonary hypertension (PH)
is a common finding but its causes are poorly understood.
Objective: To analyse in a large series of Scim. the constellation of ana-
tomic anomalies and their potential relation with PH and outcome.
Methods: From 1985 to 2010, we reviewed 90 consecutive cases of Scim
for presenting symptoms, cardiac phenotype, extracardiac anomalies, surgical
procedures and outcome. We also reviewed right heart catheterisation (RHC)
for pulmonary hypertension (PH) when it had been performed.
Results: We identified 90 cases (53 females, 37 males) with Scim. Diag-
nosis was done in fetus in 10 pts, at birth in 25 pts, before 1 year of age in
34 pts, and after 1 year of age in 21 pts. 48/90 had an associated cardiac
defect. The abnormal pulmonary venous return of the right lung was complete
in 65 pts. Associated anomalies of systemic veins were present in 13 pts. Con-
genital stenosis of the scimitar vein was found in 10 pts and aberrant drainage
in 2 pts. Systemic arterial supply to the right lung was present in 75 and con-
sidered significant in 60 pts. Extracardiac malformations were present in
21 pts including 7 diaphragmatic defects and 9 vertebral anomalies. 73 RHC
had been performed (the remaining 17 pts had normal estimation of pulmo-
nary pressures on echo): 51 pts had PH at time of diagnosis; PH had different
causes that were frequently associated: PPHN in 17 neonates, PH due to mas-
sive overflow by the systemic supply in 10 pts; PH due to associated CHD in
7; postcapillary PH in 4; respiratory disease in 3; and finally, pulmonary arte-
rial hypertension was observed in 26 pts with or without associated CHD.
There were 24 deaths (18 neonates) that were directly related to refractory PH/
cardiac failure in 9 pts, and to severe respiratory disease in 4.
Conclusion: Mortality was high in our series and beside associated CHD,
the management of PH of multifactorial origin is a remaining challenge.
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Epidemiological data relative to pulmonary arterial hypertension (PAH)
associated with congenital heart disease (CHD) are scarce
Objective: To analyze PAH associated with CHD in patients enrolled in
the second prospective PAH registry that was initiated by the French PAH net-
work in November 2006.
Methods: PAH-related clinical and outcome data were analyzed from the
registry. History and characteristics of CHDs were reviewed from the patients’
files by cardiopediatricians.
Patients and results: 3987 patients with pulmonary hypertension were
enrolled in 26 PAH centers, of whom 2585 had PAH. CHD-PAH (n=255)
accounted for 9.8% of PAH, including 95 isolated pre-tricuspid shunts (mainly
ASD), 134 isolated post-tricuspid shunts (mainly VSD), 11 combined pre-and
post-tricuspid shunts and 15 complex CHD. 60% of pts were females. Mean
age at study entry was 37 years, with 51 pts<18 years of age and 39>60 years
of age. With regards to age at diagnosis of CHD, 2 peaks were observed: <1 year
(mainly diagnosis of VSD) and 30-50 years (mainly diagnosis of ASD). 23 pts
had undergone palliative surgery, and 60 corrective procedures. The diagnosis
of PAH was done with the diagnosis of CHD in 37% of the cases (mainly
ASD and PDA) and in 60% PAH appeared during the follow-up of the CHD;
in 10 pts the diagnosis of CHD was done after the diagnosis of PAH. PAH-spe-
cific characteristics at study entry were: 52% NYHA III-IV functional class (FC),
6MWD 370±105 m, mPAP 59±20 mmHg, cardiac index 2,7±1.1 L/min/m2, PVR
12.5±10.3 WU at right heart catheterization (n=210). 47.1% of NYHA II pts
and 42.8% of NYHA III pts were not receiving PAH-specific therapies. In
treated pts (n = 164), NYHA FC improved (59% in NYHA FC I-II at last
follow-up). During the 3-year follow-up period, 20 pts died (mainly of sudden
death and right heart failure) and 7 pts were transplanted.
Conclusions: PAH is a complication of a previously known CHD in 60%
of cases. ASD is the main CHD that is diagnosed concomitantly or after PAH.
RHC is not performed systematically in CHD-PAH pts. Less than a half of
NYHA III pts are offered PAH-specific therapies. Mortality was low during
the short period of follow-up.
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Background: Assessing the exact morphology of tricuspid valve (TV)
remains a major challenge in case of Ebstein’s malformation. As the delami-
nation failure may involve one or more leaflets of the TV, this anomaly is
characterized by a great variability of its anatomy and function. Three-dimen-
sional echocardiography (3DE) seems to be interesting to depict accurately the
leaflets, the commissures and the orifice of the TV. 
Objectives: To assess the feasibility and the efficiency of 3DE to appre-
ciate the anatomy of the TV in case of Ebstein’s anomaly. Patients and
methods: It was a monocentric prospective study. 14 consecutive children (<
18 years) with a 2DE diagnosis of Ebstein’s malformation were included. X-
plane mode, 3D live and full-volume acquisitions were performed. Multi-
planar review mode was used during the off-line analysis. 
Results: Median age was 3.1 years (IQR, 0.4-9.9). Feasibility of the com-
plete 3D analysis was 93% (13/14). Median time of the off-line analysis was
12.3 minutes (IQR, 9.3-15.2). According to 3DE, the diagnosis of tricuspid
dysplasia was stated for 3 patients. 3DE allowed a good visualization of the
